Thursday 05 November, 2009
Neuropharm Group PLC
Holding(s) in Company
RNS Number : 0136C Neuropharm Group PLC 05 November 2009
|
For immediate release
|
5 November 2009
|
Neuropharm Group plc
("Neuropharm" or the "Company")
TR-1: Notification of Major Interests in Shares
|
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
|
Neuropharm Group plc
|
|
2. Reason for the notification
|
|
|
An acquisition or disposal of voting rights
|
Yes
|
|
Other (please specify):
|
Disclosure of holdings follows the sale of Insight Investment Management Limited on 2 November 2009. This notification supersedes any notifications previously issued by Lloyds Banking Group plc.
|
|
3. Full name of person(s) subject to the notification obligation:
|
Lloyds Banking Group plc
|
|
4. Full name of shareholder(s) (if different from 3.):
|
See Section 9.
|
|
5. Date of the transaction and date on which the threshold is crossed or reached:
|
02 November 2009
|
|
6. Date on which issuer notified:
|
04 November 2009
|
|
7. Threshold(s) that is/are crossed or reached:
|
N/A - direct/indirect holdings remain above 9%
|
|
8. Notified details:
|
|
|
A: Voting rights attached to shares
|
|
Class/type of shares
if possible using the ISIN CODE
|
Situation previous to the Triggering transaction
|
Resulting situation after the triggering transaction
|
|
Number of Shares
|
Number of Voting Rights
|
Number of shares Direct
|
Number of voting rights
|
% of voting rights
|
|
Direct
|
Indirect
|
Direct
|
Indirect
|
|
Ord 10p Shares
|
3,036,615
|
3,036,615
|
1,328,394
|
1,328,394
|
1,708,222
|
4.212%
|
5.417%
|
|
GB00B1NPJJ01
|
|
B: Financial Instruments
|
|
Resulting situation after the triggering transaction
|
|
Type of financial instrument
|
Expiration date
|
Exercise/ Conversion Period/ Date
|
Number of voting rights that may be acquired if the instrument is exercised/ converted
|
% of voting rights
|
|
|
|
|
|
|
|
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
|
|
Resulting situation after the triggering transaction
|
|
Type of financial
instrument
|
Exercise price
|
Expiration date
|
Number of voting rights instrument refers to
|
% of voting rights
|
|
|
|
|
|
|
|
Total (A+B+C)
|
|
Number of voting rights
|
% of voting rights
|
|
3,036,616
|
9.629%
|
|
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
|
|
3,036,607 shares (9.629%) are under the control of Scottish Widows Investment Partnership Ltd, a wholly owned subsidiary of Scottish Widows Group Ltd, a wholly owned subsidiary of Lloyds TSB Bank plc, a wholly owned subsidiary of Lloyds Banking Group plc (Direct/Indirect Interests).
Within these holdings 22,658 shares (0.072%) are managed on behalf of Clerical Medical Managed Funds Limited a wholly owned subsidiary of Clerical Medical Investment Group Limited, and a further 1,305,727 shares (4.140%) are managed on behalf of Clerical Medical Investment Group Limited, a wholly owned subsidiary of HBOS Financial Services Limited, a wholly owned subsidiary of HBOS Insurance & Investment Group Limited a wholly owned subsidiary of HBOS plc, a wholly owned subsidiary of Lloyds Banking Group plc, These holdings are therefore disclosed as an overall Direct Interest.
|
|
Proxy Voting:
|
|
10. Name of the proxy holder:
|
N/A
|
|
11. Number of voting rights proxy holder will cease to hold:
|
N/A
|
|
12. Date on which proxy holder will cease to hold voting rights:
|
N/A
|
|
13. Additional information:
|
Notification using the Total Voting Rights figure of 31,536,697
|
|
14. Contact name:
|
Matthew Wilson
|
|
15. Contact telephone number:
|
0113 235 7729
|
This information is provided by RNS
The company news service from the London Stock Exchange END HOLUVSWRKBRARRA
|
|